Skip to main content

Advertisement

SpringerLink
Log in

Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma

  • Orginal Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

We report the case of a 59-year-old man with advanced renal cell carcinoma who developed bilateral papilledema while on therapy with sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI). While papilledema has been reported in association with another TKI (imatinib), the association between sunitinib and papilledema has not previously been reported in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007;18(Suppl 10):x25–31.

    Article  PubMed  Google Scholar 

  2. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24(35):5601–8.

    Article  PubMed  CAS  Google Scholar 

  3. Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–24.

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24. Epub 2005 Dec 5.

    Article  PubMed  CAS  Google Scholar 

  5. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  PubMed  CAS  Google Scholar 

  6. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev. 2009;35(3):297–307. Epub 2009 Feb 26.

    Article  PubMed  CAS  Google Scholar 

  7. Hutson TE, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13(10):1084–96. Epub 2008 Oct 6.

    Article  PubMed  CAS  Google Scholar 

  8. Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J. 2009;39(5):341–2. Epub 2009 Apr 20.

    Article  PubMed  CAS  Google Scholar 

  9. Kapiteijn E, et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007;18(10):1745–7.

    Article  PubMed  CAS  Google Scholar 

  10. Martín G, Bellido L, Crux JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25(23):3559.

    Article  PubMed  Google Scholar 

  11. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205–10.

    Article  PubMed  Google Scholar 

  12. Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.

    Article  PubMed  CAS  Google Scholar 

  13. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357(3):258–65.

    Article  PubMed  CAS  Google Scholar 

  14. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008;52(4):331–3. Epub 2008 Sep 5.

    Article  PubMed  Google Scholar 

  15. Breccia M, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2008;32(7):1022–5. Epub 2007 Dec 3.

    Article  PubMed  CAS  Google Scholar 

  16. Larson JS, Bergstrom LK, Cameron JD, Erickson LA, Grimm TE. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthal. 2007;125(7):985–6.

    Article  PubMed  Google Scholar 

  17. Esmaeli B, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95(4):881–7.

    Article  PubMed  Google Scholar 

  18. Kusumi E, et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia. 2004;18(6):1138–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ballarat Base Hospital, Drummond Street North, Ballarat, VIC, 3350, Australia

    Jaclyn Yoong, Geoffrey Chong & K. Hamilton

  2. Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St. Andrew’s Place, East Melbourne, VIC, 3002, Australia

    Jaclyn Yoong

Authors
  1. Jaclyn Yoong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey Chong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoong, J., Chong, G. & Hamilton, K. Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma. Med Oncol 28 (Suppl 1), 395–397 (2011). https://doi.org/10.1007/s12032-010-9719-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9719-5

Keywords

Search

Navigation